Immunosynthen, Mersana’s proprietary STING agonist platform, generates systemically administered ADCs that locally activate STING signaling in both tumor-resident immune cells and in antigen expressing cells, unlocking the anti-tumor potential of innate immune stimulation. Through the delivery of a novel immunomodulatory STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery and tolerability.
Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen ADCs involves the targeted activation of the STING pathway in both tumor-resident immune cells and in tumor cells, in an antigen binding-dependent manner. This “one-two punch” provides the potential for enhanced anti-tumor activity when compared to other innate immune approaches that activate only the immune cells. Further, we have generated preclinical data across multiple targets and tumor models showing complete regression of tumors in vivo after a single low, well-tolerated dose, consistent with increased cytokine expression and immune cell infiltration within the tumor and immune memory. In addition, we have demonstrated the tolerability and favorable pharmacokinetic profile of Immunosynthen ADCs in non-human primates, after multiple IV doses and at exposures significantly higher than those required for robust efficacy in mice.
To learn more, see our Immunosynthen STING-Agonist ADC Platform and Pipeline webinar
We are building a deep pipeline of Immunosynthen ADCs for a broad range of clinical indications and potential partnerships. Our lead Immunosynthen ADC development candidate, XMT-2056, is expected to enter a Phase 1 dose escalation clinical trial in the second half of 2022.